Abstract
Inflammation is part of the body's response to internal and external environmental stimuli that normally eliminate the aggressor agent and restore the tissue physiology. However, when it becomes chronic, it can cause several pathologies such as cardiovascular, diabetes, rheumatoid arthritis, Alzheimer's autoimmune diseases and cancer. Currently, epidemiological data indicate that over 25% of all cancers are related to chronic infections and other types of unresolved inflammation. Further evidence of this relationship is the fact that prolonged use of non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with reduced risk to developing many types of cancers. Some randomized trials have shown that NSAIDs have protective action against colon adenomas, breast, prostate, and lung cancers. The inflammation present on tumor microenvironment is characterized by leukocyte infiltration, ranging in size, distribution and composition, as: tumor-associated macrophages (TAM), mast cells, dendritic cells, natural killer (NK) cells, neutrophils, eosinophils and lymphocytes. These cells produce a variety of cytotoxic mediators such as reactive oxygen and nitrogen species (ROS and RNS respectively), serine and cysteine proteases, membrane perforating agents, matrix metalloproteinase (MMP), tumor necrosis factor α (TNFα), interleukins (IL-1, IL-6, IL-8), interferons (IFNs) and enzymes, as cyclooxygenase-2 (COX-2), lipooxygenase-5 (LOX-5) and phospholipase A2 (PLA2), which activate or are activated by transcription factors as nuclear factor κB (NF-κB) and signal transducers and activators of transcription-3 (STAT3). Initially this paper will briefly review the main mediators present on tumor microenvironment, addressing the cytokines, chemokines, transcription factors, eicosanoid, and kinins and later, will present an overview of the role of inflammation in the different steps of carcinogenesis.
Keywords: Cancer, inflammation, tumor microenvironment, carcinogenesis, eicosanoids, kinins, cytokines, chemokines, transcription factors, non-steroidal anti-inflammatory drugs (NSAIDs).
Current Pharmaceutical Design
Title:Molecular Link Mechanisms between Inflammation and Cancer
Volume: 18 Issue: 26
Author(s): D. B. Vendramini-Costa and J. E. Carvalho
Affiliation:
Keywords: Cancer, inflammation, tumor microenvironment, carcinogenesis, eicosanoids, kinins, cytokines, chemokines, transcription factors, non-steroidal anti-inflammatory drugs (NSAIDs).
Abstract: Inflammation is part of the body's response to internal and external environmental stimuli that normally eliminate the aggressor agent and restore the tissue physiology. However, when it becomes chronic, it can cause several pathologies such as cardiovascular, diabetes, rheumatoid arthritis, Alzheimer's autoimmune diseases and cancer. Currently, epidemiological data indicate that over 25% of all cancers are related to chronic infections and other types of unresolved inflammation. Further evidence of this relationship is the fact that prolonged use of non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with reduced risk to developing many types of cancers. Some randomized trials have shown that NSAIDs have protective action against colon adenomas, breast, prostate, and lung cancers. The inflammation present on tumor microenvironment is characterized by leukocyte infiltration, ranging in size, distribution and composition, as: tumor-associated macrophages (TAM), mast cells, dendritic cells, natural killer (NK) cells, neutrophils, eosinophils and lymphocytes. These cells produce a variety of cytotoxic mediators such as reactive oxygen and nitrogen species (ROS and RNS respectively), serine and cysteine proteases, membrane perforating agents, matrix metalloproteinase (MMP), tumor necrosis factor α (TNFα), interleukins (IL-1, IL-6, IL-8), interferons (IFNs) and enzymes, as cyclooxygenase-2 (COX-2), lipooxygenase-5 (LOX-5) and phospholipase A2 (PLA2), which activate or are activated by transcription factors as nuclear factor κB (NF-κB) and signal transducers and activators of transcription-3 (STAT3). Initially this paper will briefly review the main mediators present on tumor microenvironment, addressing the cytokines, chemokines, transcription factors, eicosanoid, and kinins and later, will present an overview of the role of inflammation in the different steps of carcinogenesis.
Export Options
About this article
Cite this article as:
B. Vendramini-Costa D. and E. Carvalho J., Molecular Link Mechanisms between Inflammation and Cancer, Current Pharmaceutical Design 2012; 18 (26) . https://dx.doi.org/10.2174/138161212802083707
DOI https://dx.doi.org/10.2174/138161212802083707 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel, Acidic CCR2 Receptor Antagonists: Lead Optimization
Letters in Drug Design & Discovery AlphaScreen™ Kinase HTS Platforms
Current Medicinal Chemistry Comparison of <i>In Vitro</i> and <i>In Vivo</i> Effects of Infliximab on Cytokine Production in Proliferating CD4+ T Cells in Patients with Rheumatoid Arthritis
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Regulatory T Cells and Cancer Therapy: An Old Story with a New Hope
Current Cancer Therapy Reviews A Bioinorganic Perspective on Matrix Metalloproteinase Inhibition
Current Topics in Medicinal Chemistry Therapeutic Applications of Liposomal Based Drug Delivery and Drug Targeting for Immune Linked Inflammatory Maladies: A Contemporary View Point
Current Drug Targets Angiogenesis as Risk Factor for Plaque Vulnerability
Current Pharmaceutical Design Proniosomes in Transdermal Drug Delivery
Current Pharmaceutical Design Monoclonal Antibodies: A New Era in the Treatment of Non-Hodgkins Lymphoma
Current Pharmaceutical Biotechnology Biology of PPARγ in Cancer: A Critical Review on Existing Lacunae
Current Molecular Medicine Metalloproteinases: potential therapeutic targets for rheumatoid arthritis
Endocrine, Metabolic & Immune Disorders - Drug Targets The Multi-faceted Profile of Corticotropin-releasing Factor (CRF) Family of Neuropeptides and of their Receptors on the Paracrine/Local Regulation of the Inflammatory Response
Current Molecular Pharmacology Pharmacological Targets for the Inhibition of Neurogenic Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Current Biological Therapies for Inflammatory Bowel Disease
Current Pharmaceutical Design Matrix Metalloproteinase Knockout Studies and the Potential Use of Matrix Metalloproteinase Inhibitors in the Rheumatic Diseases
Current Drug Targets - Inflammation & Allergy Extracts and Flavonoids of <i>Passiflora</i> Species as Promising Anti-inflammatory and Antioxidant Substances
Current Pharmaceutical Design Time Recall; Future Concept of Chronomodulating Chemotherapy for Cancer
Current Pharmaceutical Biotechnology Phospholipase Cγ Signaling in Bone Marrow Stem Cell and Relevant Natural Compounds Therapy
Current Stem Cell Research & Therapy Anti-Angiogenic Therapy in Renal Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery α7 Nicotinic Acetylcholine Receptors: A Therapeutic Target in the Structure Era
Current Drug Targets